ClinicalTrials.gg
RecruitingNCT07164313Updated Oct 5, 2026

A Study of ZW251 in Participants With Advanced Solid Tumors

A Phase 1 interventional study of ZW251 in Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer and Germ Cell Tumor, sponsored by Zymeworks BC Inc.. Recruiting at 25 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Zymeworks BC Inc. (part of Zymeworks) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Updated Oct 5, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
140
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 926 studies in Carcinoma, Hepatocellular with a site in United States — 160 open to participants now, 245 under way, 17 of them phase 3. Carcinoma, Hepatocellular · United States.

Planned enrollment
143rd of 775
140 · median 36
Started
2025
with 38 others
Phase 1
224 of 926
26 open now
Primary completion
2027-09
later than 131 of 244 live
Registered
888th of 926
by date

Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, this one is the 143rd largest by planned enrollment of the 775 interventional ones that give a count, is one of 39 that started in 2025, is one of 224 in phase 1, reaches primary completion later than 131 of the 244 other live ones, and was the 888th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

160 of the 926 studies in Carcinoma, Hepatocellular with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 926 studies in Carcinoma, Hepatocellular with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).

Read the detailed description

Part 1 (dose escalation) of the study will evaluate the safety and tolerability of ZW251 in HCC, squamous cell NSCLC, and GCT. Part 2 (dose optimization) of the study will further assess safety and potential anti-tumor activity of the ZW251 established recommended doses in HCC.

03

Conditions studied

  • Hepatocellular Carcinoma
  • Squamous Cell Non-Small Cell Lung Cancer
  • Germ Cell Tumor

Keywords

  • GPC3-expressing cancer
  • hepatocellular carcinoma
  • antibody drug conjugate
  • ADC
  • Lung Cancer
  • Non-Small Cell Lung Cancer
  • Squamous Cell Cancer
  • Germ Cell Tumor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of HCC with evidence of locally advanced (unresectable, and ineligible for transplant) and/or disease. Noninvasive methods may be used to confirm diagnosis
  • Pathologically or cytologically confirmed diagnosis of squamous cell NSCLC with evidence of locally advanced (unresectable) and/or metastatic disease
  • Pathologically or cytologically confirmed diagnosis of GCT with evidence of yolk sac and/or choriocarcinoma predominant component and locally advanced (unresectable) and/or metastatic disease
  • per v1.1
  • (ECOG) Performance Status score of 0 or 1
  • Liver function status of Class A (for HCC only)
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Known additional that is progressing or that has required active treatment within the last year
  • History of hepatic encephalopathy within the past 6 months or requirement for medications to control encephalopathy
  • Participants with HCC experiencing main portal vein tumor invasion require sponsor approval for enrollment
  • Known gastrointestinal bleeding within 3 months
  • Acute or chronic uncontrolled renal disease, pancreatitis, or non-malignant liver disease
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    ZW251

    Drug: ZW251

Interventions

  • DrugZW251

    Administered intravenously

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicities (DLTs; Part 1)

    Number of participants who experienced a DLT. DLTs include specifically defined adverse events (AEs) considered to be related to ZW251

    Time frame: Up to 3 weeks

  2. Incidence of AEs (Parts 1 and 2)

    Number of participants who experienced AEs, adverse events of special interest, or serious adverse events

    Time frame: Up to approximately 2 years

  3. Incidence of clinical laboratory abnormalities (Parts 1 and 2)

    Number of participants who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology or chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0

    Time frame: Up to approximately 2 years

  4. Objective response rate (Part 2)

    Number of participants who achieved a best overall response of either confirmed complete response (CR) or partial response (PR) during treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Objective response rate (Part 1)

    Number of participants who achieved a best overall response of either confirmed CR or PR during treatment according to RECIST v1.1

    Time frame: Up to approximately 2 years

  2. Best overall response (Parts 1 and 2)

    Time frame: Up to approximately 2 years

  3. Disease control rate (Parts 1 and 2)

    Number of participants who achieved a best response of CR, PR, or stable disease during treatment per RECIST v1.1

    Time frame: Up to approximately 2 years

  4. Duration of response (Parts 1 and 2)

    The time from the first objective response (CR or PR) to the first documented progressive disease (PD) per RECIST v1.1 or death within 30 days of last dose of study treatment from any cause. Only participants who achieve a confirmed response will be included in the analysis

    Time frame: Up to approximately 2 years

  5. Progression-free survival (Part 2)

    The time from the first dose of study treatment to the date of first documented PD per RECIST v1.1 or death from any cause

    Time frame: Up to approximately 2 years

  6. Area under the concentration-time curve (AUC0-504) of ZW251 (Parts 1 and 2)

    Area under the concentration-time curve of ZW251 after first dose administration

    Time frame: Up to approximately 2 years

  7. Maximum concentration (Cmax) of ZW251 (Parts 1 and 2)

    ZW251 maximum concentration after first dose administration

    Time frame: Up to approximately 2 years

  8. Area under the concentration-time curve of ZW251 at steady state (AUCtau,ss; Parts 1 and 2)

    Area under the concentration-time curve of ZW251 at steady state after fourth dose administration

    Time frame: Up to approximately 2 years

  9. Maximum concentration of ZW251 at steady state (Сmax,ss; Parts 1 and 2)

    ZW251 maximum concentration at steady state after fourth dose administration

    Time frame: Up to approximately 2 years

  10. Minimal concentration of ZW251 at steady state (Сmin,ss; Parts 1 and 2)

    ZW251 minimal concentration at steady state after fourth dose administration

    Time frame: Up to approximately 2 years

  11. Incidence of anti-drug antibodies (ADAs; Parts 1 and 2)

    Number of participants who develop ADAs

    Time frame: Up to approximately 2 years

07

Study locations

25 of 25 sites recruiting
  • UCSF Comprehensive Cancer Center
    San Francisco, California 94158, United States
    Recruiting
    • Katie Kelley, MD · Principal investigator
  • University of California Los Angeles - Cancer Care - Santa Monica (UCLA)
    Santa Monica, California 90404, United States
    Recruiting
    • Richard Finn, MD · Principal investigator
  • Norton Cancer Institute
    Louisville, Kentucky 40202, United States
    Recruiting
    • John Hamm, MD FACP, FASCO · Principal investigator
  • START Midwest
    Grand Rapids, Michigan 49546, United States
    Recruiting
    • Sreenivasa Chandana, MD, PhD · Principal investigator
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
    Recruiting
    • Martin Gutierrez, MD · Principal investigator
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065-6800, United States
    Recruiting
    • Ghassan Abou-Alfa, MD, JD, MBA, PhD · Principal investigator
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • Ecaterina Dumbrava, MD · Principal investigator
  • START San Antonio
    San Antonio, Texas 78229, United States
    Recruiting
    • Muralidhar Beeram, MD, MBBS · Principal investigator
  • START - Dublin Mater Misericordiae University Hospital (MMUH)
    Dublin, D07 R2WY, Ireland
    Recruiting
    • Austin Duffy, MD, DMed · Principal investigator
  • National Cancer Center East
    Kashiwa, 2778577, Japan
    Recruiting
    • Masafumi Ikeda, MD, PhD · Principal investigator
  • Kyoto University Hospital
    Kyoto, 606-8507, Japan
    Recruiting
    • Takako Nakajima, MD · Principal investigator
  • Kansai Medical University Hospital
    Osaka, 573-1191, Japan
    Recruiting
    • Toshio Shimizu, MD, PhD · Principal investigator
  • National Cancer Center Hospital
    Tokyo, 104-0045, Japan
    Recruiting
    • Yuta Maruki, MD · Principal investigator
  • START Lisboa a - Unidade de Ensaios ClÃnicos - Hospital de Santa Maria
    Lisbon, 1649-035, Portugal
    Recruiting
    • Andre Mansinho, MD, MSc · Principal investigator
  • Unidade Local de Saúde Gaia e Espinho
    Vila Nova de Gaia, 4434-502, Portugal
    Recruiting
    • Andreia Capela, MD · Principal investigator
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
    Recruiting
    • Jaume Capdevila Castillon, MD, PhD · Principal investigator
  • START Barcelona
    Barcelona, 29010, Spain
    Recruiting
    • Tatiana Hernandez Guerrero, MD, PhD · Principal investigator
  • START - Rioja Hospital Universitario San Pedro
    Logroño, 26006, Spain
    Recruiting
    • Maria Jose de Miguel Luken, MD · Principal investigator
  • START Madrid Hospital Universitario Fundacion Jimenez Diaz
    Madrid, 28040, Spain
    Recruiting
    • Manuel Pedregal Trujillo, MD · Principal investigator
  • START Madrid Hospital Universitario HM Sanchinarro - CIOCC
    Madrid, 28050, Spain
    Recruiting
    • Emiliano Calvo, MD, PhD · Principal investigator
  • NEXT Oncology Madrid
    Madrid, 28223, Spain
    Recruiting
    • Valentina Boni, MD, PhD · Principal investigator
  • Hospital Universitario Virgen de la Victoria
    Málaga, 29010, Spain
    Recruiting
    • Javier Garcia Corbacho, MD · Principal investigator
  • Clinica Universidad de Navarra
    Pamplona, 31008, Spain
    Recruiting
    • Bruno Sangro, MD, PhD · Principal investigator
  • National Taiwan University Hospital
    Taipei, 100225, Taiwan
    Recruiting
    • Ann Lii Cheng, MD · Principal investigator
  • Taipei Veterans General Hospital
    Taipei, 112201, Taiwan
    Recruiting
    • Yi-Hsiang Huang, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Sep 2027, 23 months after the start.

Of 103 industry-sponsored phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 23 months is below that.

Counting every sponsor, half of 249 studies reached it within 49 months; a quarter within 32 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Sep 10, 2025
StartActual
Oct 21, 2025
Primary completionEst.
Sep 2027
CompletionEst.
May 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
100→140
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Enrollment 100→140
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07164313
Lead sponsor
Zymeworks BC Inc.
Responsible party
Sponsor
First posted
Sep 10, 2025
Start date
Oct 21, 2025
Primary completion
Sep 2027 (estimated)
Completion
May 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Zymeworks Clinical Trial Resource
Contact
medinfo@zymeworks.com
(206) 237-1030
Maggie Weinstein, MD, PhD, MPH
study director · Zymeworks BC Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion